Alliance for Regenerative Medicine Releases Annual Industry Report Showcasing Impressive Sector Growth

WASHINGTON, DC--(Marketwired - Apr 29, 2014) - The Alliance for Regenerative Medicine (ARM) today announced the release of its 3^rd Regenerative Medicine Annual Industry Report, an in-depth review of the continued growth and advancements in the regenerative medicine (RM) sector during the past year. The report provides a detailed overview of available RM and advanced therapy products, clinical trial breakdown by therapeutic category, anticipated 2014 milestones and financial performance across the sector. Key findings from ARM's Pharmaceutical and Large-Cap Biotech Survey, another recent report exploring strategic viewpoints and perspectives on RM from interviews conducted with executives at 16 top companies, are also highlighted.

The Regenerative Medicine Annual Industry Report is available online at http://alliancerm.org/news/download-must-have-industry-report and in a limited print edition. The report's release coincides with ARM's 5^th Annual Dinner and Legislative Fly-In (April 28-29 in Washington DC). This event is a yearly gathering of ARM's key stakeholders including patient advocates, disease-foundation executives, and corporate and government representatives. The Annual Dinner celebrates major accomplishments in RM over the past year, while the Legislative Fly-In serves as the organization's largest in-person advocacy effort.

The combined RM field, including cell, gene and gene modified cell therapies, generated $4.7 billion through deals, acquisitions and public and private investments from March 2013 to March 2014. This reflects the sector's strong potential for the treatment of chronic and life threatening diseases -- today, there is a growing number of marketed products backed by a mature clinical pipeline including more than 247 companies developing 460 products and sponsoring more than 700 trials.

"Cell- and gene-based regenerative medicine is a hotbed of progress poised to revolutionize patient care across multiple therapeutic areas including oncology, cardiovascular and ocular diseases, wound healing, autoimmune disorders and spinal cord injuries," said Geoff MacKay, Chairman of ARM and President and CEO of Organogenesis Inc. "We are encouraged by the growth of the field in just the past 12 months as highlighted in this Industry Report, and also by the ever increasing support for regenerative medicine as evidenced by ARM's recent Pharma Survey and the newly introduced Regenerative Medicine Promotion Act in Congress. ARM reaffirms our commitment to work with regulatory agencies, policy makers and payers to deliver cost-effective, high-value therapies that improve and save lives."